65,437 trials
Colorectal Cancer · Familial Adenomatous Polyposis
Primary: Percent Change in the Number of Polyps Greater Than or Equal to 2mm in Diameter in Focal Area(s) of the Colorectum — -1; -11; -1; -13 percentage change in polyp count
Atrial Fibrillation
Primary: Number of Participants With Composite of the Following Events, Adjudicated Centrally: Stroke, Transient Ischemic Attack, Non-central Nervous System Systemic Embolism…
Colostomy Stoma · Ileostomy Stoma
Primary: Degree of Leakage — 3.6; 2.4; 5.5; 4.8 units on a scale
Smoking Cessation · Tobacco Use Disorder
Primary: Self-reported 6-month Prolonged Abstinence From Smoking — 252; 194; 109 participants
Pandemic H5N1 Influenza
Primary: Percentages Of Subjects Achieving Hemagglutinin Inhibition (HI) Titers ≥40 Against A/H5N1 Strain. — 4; 4; 85; 63 Percentages of subjects
Low Back Pain
Primary: Percent of Maximal Voluntary Isometric Contraction (%MVIC) — 73.5; 57.6; 62.7; 37 percentage of MVIC of gmax
Circulating Cell Free Fetal DNA · Intrauterine Fetal Demise · Miscarriage
Primary: The Presence or Absence of Cell Free Fetal DNA in Maternal Blood in the Setting of a Failed Pregnancy. — 50 percentage of participants
Breast Cancer
Primary: Objective Response Rate by RECIST Criteria Following — 0 participants
Diabetes Mellitus, Type 2
Primary: Change From Baseline to 16 Weeks in Mean 24-hour Systolic Blood Pressure (SBP) — -3.41; -1.70; -0.63 millimeters of mercury (mmHg) — p=<0.001
Parkinson Disease
Primary: Change From Baseline (BL) in Unified Parkinson Disease (PD) Rating Scale (UPDRS) Motor Score — -1.91; -1.58; -2.76; -4.31 Score on a scale — p=0.864
Pregnancy · Unexplained Infertility
Primary: Multiple Gestation Rate Following Recruitment of Multiple Follicular Development With an AI, as Compared to CC and FSH. — 9; 8; 34 number of multiples
Autism · Autism Spectrum Disorders
Primary: Modified Simond & Parraga Sleep Questionnaire (MSPSQ) - Composite Sleep Index — 6.53; 7.44; 4.80; 6.83 units on a scale
Familial Hypercholesterolaemia
Primary: Percent Change From Baseline in LDL-C — -37.86; -43.67; -42.88 Percentage change — p=<0.001
Moderate-to-Severe Asthma
Primary: Change in Percent Predicted FEV1 at Week 24 — 3.631; 2.000 Percent
Acromegaly
Primary: Percentage of Participants With a Reduction of Mean GH Level to <2.5 μg/L and the Normalization of IGF-1 — 31.3; 19.2; 39.4; 21.8 Percentage of Participants — p=0.007